Transglutaminase inhibitors


Transglutaminases are involved in a multitude of physiological processes. One way to explore these processes is to use specific inhibitors. In addition to naturally occurring inhibitors such as the protein tridegin, rationally designed synthetic, small molecule inhibitors such as Z-DON (Z006) will be of immeasurable help to scientists wishing to decipher the enigmatic roles of individual transglutaminases.

In the following section, Zedira’s range of transglutaminase inhibitors is introduced with a special focus on their respective mechanism of action:


DON” compounds (6-diazo-5-oxo-L-norleucine containing peptides)  
 
  2-[(2-oxo-propyl)thio]imidazolium derivatives
  read more     read more

Naturally occurring inhibitors
     
Michael acceptor peptidomimetics
read more     read more
  
Lysine analogues - chloromethyl ketones
     
read more        


  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland